États-Unis · Places boursières & cours · Nasdaq

Galderma Q3 Sales Climb; Confirms FY26 Core EBITDA Margin View, Lifts Sales Growth Outlook; Stock Up

Publié par Nasdaq · États-Unis il y a 1 h

(RTTNews) - Galderma Group AG (GALD.SW, GALDY), a Swiss pharmaceutical company, reported Thursday strong growth in third-quarter sales, with broad-based double-digit growth across…

Lire l'article complet sur Nasdaq Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.nasdaq.com)

Galderma Q3 Sales Climb; Confirms FY26 Core EBITDA Margin View, Lifts Sales Growth Outlook; Stock Up

À lire aussi

India Ramps Up Coal Supplies to Record High as Power Crisis Looms

Cardano (ADA) Down 3.2% Amid Technical Factors, No New Shocks

Retirement and Long-Term Care Planning for People Without Kids

State of the Options Industry Q3 2026: Volume Growth Concentrated in Index and ETF Options

Developer’s guide to implementing MCP apps in Gemini

Galderma Q3 Sales Climb; Confirms FY26 Core EBITDA Margin View, Lifts Sales Growth Outlook; Stock Up

Partager

À lire aussi

India Ramps Up Coal Supplies to Record High as Power Crisis Looms

Cardano (ADA) Down 3.2% Amid Technical Factors, No New Shocks

Retirement and Long-Term Care Planning for People Without Kids

State of the Options Industry Q3 2026: Volume Growth Concentrated in Index and ETF Options

Developer’s guide to implementing MCP apps in Gemini